Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5827757 | 1.00 | SLC6A3 (0.34) | SLC6A3SLC6A4SLC6A2ALDH1A1USP2 | |
| SCHEMBL6519091 | 0.92 | — | — | |
| SCHEMBL15730429 | 0.82 | USP2 (0.32) | ALDH1A1USP2LMNACYP1A2TSHR | |
| SCHEMBL21028163 | 0.80 | SLC6A3 (0.34) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL15730444 | 0.79 | — | — | |
| SCHEMBL4492198 | 0.78 | DPP4 (0.35) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL9189986 | 0.78 | SLC6A4 (0.31) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL7568293 | 0.76 | — | — | |
| SCHEMBL29322047 | 0.76 | SLC6A4 (0.31) | SLC6A3SLC6A4 | |
| SCHEMBL4497021 | 0.75 | DPP4 (0.33) | SLC6A3SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034016-B2 | 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives | ALMIRALL PRODESFARMA, S.A. (ES) | 2006-04-25 | — | — | US | disclosed |
| EP-1198464-B1 | 8-PHENYL-6,9-DIHYDRO-[1,2,4]TRIAZOLO[3,4-i]PURIN-5-ONE DERIVATIVES | ALMIRALL PRODESFARMA SA (ES) | 2003-10-08 | — | — | EP | disclosed |
| US-20030060627-A1 | 8-Phenyl-6, 9-dihydro-[1,2,4] triazolo[3,4-i]purin-5-one derivatives | ALMIRALL PRODESFARMA, S.A. (ES) | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060627-A1 | 8-Phenyl-6, 9-dihydro-[1,2,4] triazolo[3,4-i]purin-5-one derivatives | HYOU1, CHN2, PURB | SLC6A3 1330/4885SLC6A4 1575/4885SLC6A2 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.